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Abstract
Receptor-mediated endocytosis is a highly efficient mechanism for cellular uptake of membrane-
impermeant ligands. Cells use this process to acquire nutrients, initiate signal transduction,
promote development, regulate neurotransmission, and maintain homeostasis. Natural receptors
that participate in receptor-mediated endocytosis are structurally diverse, ranging from large
transmembrane proteins to small glycolipids embedded in the outer leaflet of cellular plasma
membranes. Despite their vast structural differences, these receptors share common features of
binding to extracellular ligands, clustering in dynamic membrane regions that pinch off to yield
intracellular vesicles, and accumulation of receptor-ligand complexes in membrane-sealed
endosomes. Receptors typically dissociate from ligands in endosomes and cycle back to the cell
surface, whereas internalized ligands are usually delivered into lysosomes, where they are
degraded, but some can escape and penetrate into the cytosol. Here, we review efforts to develop
synthetic cell surface receptors, defined as nonnatural compounds, exemplified by mimics of
cholesterol, that insert into plasma membranes, bind extracellular ligands including therapeutics,
probes, and endogenous proteins, and engage endocytic membrane trafficking pathways. By
mimicking natural mechanisms of receptor-mediated endocytosis, synthetic cell surface receptors
have the potential to function as prosthetic molecules capable of seamlessly augmenting the
endocytic uptake machinery of living mammalian cells.
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1. Receptor-mediated endocytosis
The plasma membrane of eukaryotic cells represents a universal barrier that protects fragile
intracellular structures from toxic or detrimental extracellular materials. Whereas small
hydrophobic molecules can often penetrate this lipid bilayer through passive diffusion, polar
amino acids, sugars and ions must interact with specific membrane-bound protein pumps or
channels to access the cell interior. Other cell-impermeable small molecules,
macromolecules, and particles, must be actively taken up by cells, with regions of the
plasma membrane functioning to capture solutes by invaginating and pinching off to form
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intracellular vesicles. This process, termed endocytosis, represents multiple related
mechanisms for the internalization of extracellular molecules.[1–3] These mechanisms
include phagocytosis, where specific cell types engulf large particles, pinocytosis, where
small regions of cellular plasma membranes are actively invaginated to capture solutes, and
receptor-mediated endocytosis (RME). In RME, internalizing receptors on the cell surface
bind cell-impermeable ligands to concentrate these ligands in the cell, providing a
mechanism of cellular uptake that is thousands of times more efficient than non-specific
pinocytosis.
Receptors involved in RME comprise a structurally diverse group of biomolecules. These
receptors range from macromolecular proteins that span the plasma membrane to small
glycolipids, anchored only to the plasma membrane outer leaflet. Cell-impermeable small
molecules, lipids, peptides, proteins, nucleic acids, and carbohydrates can be internalized by
RME, enabling the consumption of nutrients, elimination of pathogens, and termination of
signals initiated by extracellular stimuli. By exploiting RME, certain viruses, protein toxins,
and other pathogens invade cells and cause disease.[4] These pathogens include simian
virus-40 (SV40), which enters cells through RME upon binding to the small glycolipid
ganglioside GM1 (M.W. 1603 g/mol). Figure 1 shows structures of the protein capsid of this
virus[5] and a side view of the VP1 pentamer subunit[6] that binds the pentasaccharide head
group of ganglioside GM1. This figure also shows structures of extracellular regions and
representations of other receptors involved in RME such as the membrane-spanning low-
density lipoprotein (LDL) receptor,[7] the transferrin receptor (TFR),[8] and the lipid-
anchored receptor FcγRIIIB (CD16)[9] bound to or below the cognate ligands LDL,[10]
transferrin, and the Fc fragment of human IgG.
RME of cholesterol-laden LDL particles by the LDL receptor (LDLR) has been extensively
characterized,[7, 11–14] and key features of this process are illustrated in Figure 2. The
LDLR binds LDL particles defined by a core of ~1500 molecules of fatty acid-esterified
cholesterol that is encapsulated by a monolayer of free cholesterol, phospholipids,
triglycerides, and a single protein termed apolipoprotein B-100. By recognizing the protein
component of LDL, the LDLR provides a major mechanism by which vertebrate animals
internalize exogenous cholesterol, a key building block required for the biosynthesis of
steroid hormones and bile acids, and the assembly of cellular membranes. By binding the
cytosolic protein clathrin, the LDLR clusters in clathrin-coated pits on the cellular plasma
membrane. Association of the LDLR with clathrin requires interactions between cytosolic
residues of this receptor with adapter proteins such as ARH,[15, 16] which associates with
phosphatidylinositol-4,5-bisphosphate at the cytofacial leaflet of the plasma membrane.
These interactions allow the LDLR to constitutively deliver LDL into membrane-sealed
vesicles that fuse to form endosomes (Figure 2). In this process, clathrin polymerizes to
form a lattice of clathrin hexagons and pentagons that surround vesicles as they bud from the
plasma membrane. Changes in membrane curvature required for vesicle budding are
stabilized both by clathrin and a number of clathrin-binding proteins including FCHO
proteins that drive flat plasma membrane segments into highly curved endocytic vesicles
loaded with cargo.[1] The pH of these internalized vesicles drops as a consequence of
activation of proton pumps and opening of chloride channels, and these vesicles fuse with
relatively short-lived acidic (pH ~ 6) sorting endosomes that accept receptor ligand
complexes.[17, 18] This decrease in pH, and the intrinsic tubular-vesicular geometry of
sorting endosomes, facilitates the dissociation of receptors from ligands.[19] Many free
receptors subsequently traffic to the endocytic-recycling compartment (ERC), a long-lived
organelle, before cycling back to the cell surface. In this way, the LDLR can be reused up to
several hundred times during its ~20-hour lifespan. Sorting endosomes containing free LDL
mature to form more acidic late endosomes (pH ~ 5.5), and these compartments
subsequently fuse with lysosomes, more acidic organelles (pH ~ 5) containing highly
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hydrolytic enzymes. Hydrolysis in lysosomes of cholesteryl esters, protein, and other
components of LDL, liberates these nutrients for utilization by the cell.[11, 12] Because
LDL is efficiently delivered to late endosomes and lysosomes (within ~ 30 min), fluorescent
complexes of LDL[20] are often used as markers for these compartments at the terminal end
of the endosomal pathway.
Clathrin-dependent endocytosis is thought to be responsible for the uptake of about half of
all ligands of cell surface receptors. These ligands include LDL, epidermal growth factor
(EGF), and transferrin (TF), a carrier of the essential nutrient iron in serum of vertebrate
animals.[1] The TF protein binds the transferrin receptor (TFR),[8] and internalization of TF
by RME results in release of iron in acidic endosomal compartments for utilization by the
cell. However, unlike LDL, the apo-TF remains bound to its receptor, the receptor-ligand
complex cycles back to the plasma membrane, and apo-TF is released from the TFR at the
neutral pH of the extracellular environment. For this reason, fluorescent transferrin
conjugates are often used to label early endosomes in studies of endocytic processes. Some
receptors including LDLR and TFR are internalized via a constitutive clathrin-dependent
pathway that does require ligand binding. In contrast, binding of EGF to the epidermal
growth factor receptor (EGFR) and subsequent receptor dimerization is required to trigger
clathrin-mediated endocytosis of this receptor.[21]
Some cell surface receptors are attached to the plasma membrane by lipids inserted into the
exofacial leaflet of the bilayer. Posttranslational modification of proteins with
glycosylphosphatidylinositol (GPI)-lipids is used to anchor receptors such as folate
receptor-2 and FcγRIIIB (CD16) on the cell surface. These receptors bind 5-
methyltetrahydrofolate[22, 23] and the invariant Fc region of immunoglobulin-G[9, 24] to
promote RME of these ligands.[25] Similarly, small glycolipids function as receptors
involved in RME. Ganglioside GM1 enables the protein cholera toxin[26] and the non-
enveloped virus SV40 to enter cells upon binding to its pentasaccharide head group.[27, 28]
Because of the lack of a direct connection to the highly efficient clathrin machinery via a
cytoplasmic region, the endocytosis of GPI-linked proteins and other lipid-linked receptors
is slower than the uptake of most transmembrane proteins, and is thought to involve
multiple, possibly simultaneous, endocytic uptake mechanisms.[28] Uptake of lipid-bound
ligands has been reported to involve lipid rafts, membrane domains enriched in cholesterol
and sphingolipids, and in some cell types include flask shaped invaginations termed
caveolae.[29] Many proteins covalently or noncovalently associated with cholesterol,
sphingolipids, or saturated lipids associate with lipid rafts that segregate and concentrate
membrane proteins, regulate signal transduction pathways, and can affect the endocytosis of
specific receptors. Many lipid-linked proteins undergo endocytosis through clathrin-
independent carriers (CLIC) and traffic through GPI-anchored protein-enriched early
endosomal compartments (GEEC).[30] Other mechanisms of clathrin-independent
endocytosis have also been reported, and this field was recently reviewed.[3, 31]
Protein toxins and viruses commonly exploit receptor-mediated endocytosis to penetrate into
the cell interior.[4] In some cases, multiple distinct endocytic mechanisms of cellular uptake
have been simultaneously observed.[32] In contrast to most protein ligands, viruses and
other pathogens internalized by RME typically avoid degradation in lysosomes, either by
engaging trafficking itineraries that bypass these organelles, by fusion of viral envelopes
with endosomal membranes to escape from endosomes, or by production of proteins or
peptides that disrupt endosomal or phagosomal membranes at low pH.[33] Here, we review
recent efforts to develop synthetic molecules with trafficking properties similar to natural
surface receptors. By inserting into cellular plasma membranes, these synthetic cell surface
receptors are designed to promote the endocytosis of endogenous ligands, therapeutics, and
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molecular probes, and in some cases have been shown to enable escape of internalized cargo
from endosomal compartments into the cytoplasm and nucleus of living cells.
2. Cellular uptake and trafficking of cholesterol-mimetic membrane anchors
Natural receptors are typically anchored to cell surfaces through either transmembrane
protein segments or attached lipids such as GPI anchors and glycosphingolipids that insert
into the exofacial leaflet of the plasma membrane. In contrast, cytoplasmic proteins are
commonly anchored to intracellular membranes via other lipids such as palmitoyl thioesters,
myristoyl amides, farnesyl and related thioethers, and cholesterol esters.[34, 35] Because of
its high abundance in cellular plasma membranes, and its role in cycling between the cell
surface and early/recycling endosomes,[36] we have focused on using analogues of
cholesterol, particularly derivatives of cholesterylamine (Figure 3), to construct synthetic
compounds that mimic cellular uptake and trafficking properties of natural cell surface
receptors. A wide variety of synthetic mimics of other natural lipids[37–41] and
peptides[42] capable of insertion into membranes of living cells have also been reported.
Cholesterol has been termed the central lipid of mammalian cells.[43] Among its many
biological roles, this sterol is critically important for stabilization of animal cell membranes.
To estimate the number of cholesterol molecules in cellular membranes, the plasma
membrane of a typical mammalian cell was modeled by Maxfield[44] as a sphere of 10 μm3
with a surface area of 3 × 108 nm2. This membrane is composed of approximately 2/3 lipid
and 1/3 protein, and based on the average surface area of a lipid of 0.6 nm2,[45] contains
about 109 lipid molecules in both leaflets.[44] Because cholesterol represents about 30% of
the lipids in the plasma membrane, the plasma membrane contains roughly 3 × 108
cholesterol molecules, corresponding to about half of the total abundance of cholesterol
(about 6 × 108 molecules) in all membranes of mammalian cells. This sterol rapidly flips
between the two leaflets of this membrane with a half-time of approximately 1 second,[46]
but the distribution of cholesterol between leaflets of the plasma membrane is asymmetric,
with a smaller fraction residing in the exofacial leaflet (~ 0.75 × 108 molecules), compared
to the cytofacial leaflet (~ 2.25 × 108 molecules).[36] Within cells, the ERC represents the
second largest reservoir of cholesterol, containing about 2 × 108 molecules of this sterol.
Photobleaching studies of the fluorescent natural product dehydroergosterol (Figure 3), a
close structural and functional mimic of cholesterol, indicate that cholesterol dynamically
cycles between the plasma membrane and ERC. In this rapid process, it has been estimated
that 1 × 106 molecules of cholesterol enter and leave the ERC per second.[47] The
cholesterol content of other mammalian organelles such as the endoplasmic reticulum
(containing ~ 5% of cellular cholesterol), the Golgi apparatus, lysosomes, and mitochondria
is much lower than the plasma membrane and ERC. This heterogeneous distribution of
cholesterol among biological membranes is thought to relate to the affinity of this sterol for
saturated and monounsaturated lipids that are highly enriched in the plasma membrane and
ERC compared to other organelles.[36]
The trafficking of cholesterol between the plasma membrane and the ERC has been
proposed to occur through both vesicular (via endocytosis) and non-vesicular mechanisms.
[44] However, a recent comparison of dehydroergosterol and fluorescent BODIPY
cholesterol (Figure 3), in BHK cells engineered to express antisense mRNA against the
heavy chain of clathrin, suggests that sterol internalization from the cell surface to the ERC
occurs predominantly through vesicular uptake dependent on clathrin-mediated endocytosis.
[48] Subsequent cycling of cholesterol from the ERC back to the plasma membrane is
thought to involve vesicular transport similar to plasma membrane recycling of natural cell
surface receptors.[44] Despite bearing a fluorophore in the tail of the sterol, BODIPY
cholesterol appears to closely mimic the membrane trafficking and cellular efflux properties
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of natural cholesterol.[48–50] In contrast, other fluorescent sterols with modified tails such
as 22-NBD cholesterol[51] and 25-NBD cholesterol[52] do not exhibit cellular trafficking
properties similar to cholesterol. The use of fluorescent sterols to study cholesterol
trafficking in living cells was recently reviewed.[53]
A wide variety of mimics and derivatives of cholesterol have been synthesized and
investigated.[54] A comparison of the biophysical properties of the nonnatural compounds
3β-amino-5-cholestene (also known as cholesterylamine or aminocholesterol, Figure 3) and
3α-amino-5-cholestene was reported by Bittman in 1992.[55] These studies revealed that
the 3β-isomer exhibits much slower biphasic vesicle exchange kinetics (t1/2=118.9 h and 9.3
h) compared with the 3α-isomer (t1/2=393.1 min and 16.1 min) and free cholesterol
(monophasic t1/2=256 min). These results suggest the possibility of unique interactions
between the 3β-isomer of cholesterylamine and phospholipids. Intrigued by these
observations, we developed a practical method to synthesize multigram quantities of 3β-
cholesterylamine,[56] and we have investigated the biological properties of a variety of its
derivatives. Some of our early work in this area[57–62] has been reviewed.[63]
Recent biophysical studies have investigated cholesterylamine in model bilayer membranes.
[64] This synthetic steroid was found to form a liquid ordered phase very similar to
cholesterol with saturated lipids, suggesting that cholesterylamine could be a good substitute
for cholesterol. Consistent with this interpretation, fluorescent N-alkyl-cholesterylamines
bearing neutral or negatively charged head groups such as Pennsylvania Green (PG)-Glu-β-
Ala-cholesterylamine (1, Figure 3) are avidly taken up by living mammalian cells, associate
with the cellular plasma membrane, and accumulate in transferrin-positive early/recycling
endosomes (Figure 4, panels A–D). Although partitioning between the plasma membrane
and early/recycling endosomes can differ depending on the structure of the head group and
linker attached to cholesterylamine,[61] many of these compounds rapidly cycle between the
plasma membrane and early/recycling endosomes. Some fluorescent cholesterylamine
derivatives exhibit plasma membrane recycling kinetics similar to cycling of the LDL
receptor, making a round trip between these two compartments in less than 10 minutes.[61]
Structurally optimized fluorescent cholesterylamines such as 1 associate avidly with the
exofacial leaflet of cellular plasma membranes and become localized in the ERC (see Figure
4, panels A–B), showing a overall distribution similar to the fluorescent cholesterol-binding
macrolide filipin.[52] Many other fluorescent analogues of cholesterol are not stably
incorporated in cellular plasma membranes. For example, confocal microscopy of Jurkat
lymphocytes treated with 22-NBD cholesterol reveals rapid trafficking of this compound to
the Golgi apparatus and nuclear membrane (see Figure 4, panels E–F).
By cycling between the plasma membrane and ERC of mammalian cells, cholesterylamines
mimic some of the major membrane trafficking properties of natural cholesterol. However,
the charged amino group of cholesterylamine also confers some significant biological
differences compared with the alcohol of cholesterol in living cells. Whereas cholesterol can
be esterified by fatty acids derived from phosphatidylcholine mediated by lecithin
cholesterol acyltransferase (LCAT) for storage in lipoproteins and lipid droplets,[65] the
predominantly protonated amino group of cholesterylamine and N-alkyl-cholesterylamine
derivatives is highly unlikely to be a substrate of this enzyme. Cholesterol also rapidly flips
between leaflets of cellular membranes,[46] whereas desolvation of the protonated amino
group of cholesterylamine engenders a substantial energetic penalty against equilibration
across the leaflet of vesicles.[55] Consistent with this observation, studies of living Jurkat
lymphocyte cells treated with N-alkyl-cholesterylamines linked the pH-sensitive
hydrophobic Tokyo Green fluorophore[66] indicate that cholesterylamines do not flip
between membrane leaflets. In these experiments, cellular fluorescence imaged by confocal
microscopy was compared in the presence and absence of Bafilomycin A1,[67] a natural
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product inhibitor of vacuolar ATPases that raises endosomal pH and allows assessment of
the abundance of the acid-sensitive Tokyo Green fluorophore in endosomes of treated cells.
If this cholesterylamine had flipped to the cytofacial leaflet of endosomes, the linked Tokyo
Green fluorophore would be exposed to the neutral pH of the cytoplasm, resulting in strong
endosomal fluorescence. These experiments indicated that despite achieving a high relative
abundance in the ERC, fluorescent cholesterylamines do not flip from the exofacial leaflet to
the cytofacial leaflet of endosomal membranes of living cells.[66] As a consequence,
cholesterylamines show dynamic membrane trafficking properties that are similar to many
cell surface receptors, projecting N-linked groups either from the cell surface into the
extracellular environment or from the exofacial leaflet of early/recycling endosomes into the
lumen of these intracellular compartments during plasma membrane recycling.[61] This
property allows the use of N-alkyl-cholesterylamines and related compounds as a platform
for the construction of mimics of cell surface receptors.
3. Synthetic cell surface receptors comprising binding motifs linked to
cholesterylamine
3.1. Fluorophores and other small protein-binding motifs
Natural receptors involved in RME share a unifying structural architecture of projection of
ligand-binding motifs from lipids or proteins embedded in the cellular plasma membrane.
The smallest of these receptors associate with the exofacial leaflet of cellular plasma
membranes through linked GPI-anchors and sphingolipids. Structures of the GPI anchor of
human erythrocyte acetylcholinesterase[68] and the much smaller glycosphingolipid
ganglioside GM1[69] are illustrated in Figure 5. To create synthetic cell surface receptors
that are similar in size to ganglioside GM1, we have synthesized N-alkyl-cholesterylamines
linked to a variety of small protein-binding motifs including fluorophores,[57, 61] peptides,
[62] biotin,[60] and metal chelators.[70] Representative examples of fluorescent (1)[71] and
metal-chelating (2)[70] derivatives of N-alkyl-cholesterylamine are shown adjacent to the
structure of ganglioside GM1 in Figure 5. Structurally similar cholesterylamines-linked to
dinitrophenyl (DNP), 7-nitrobenz-2-oxa-1,3-diazole (NBD), biotin, and nickel2+ chelated by
the NTA head group of 2 exhibit receptor-like properties, enabling synthetic receptor-
mediated endocytosis of antibodies and other proteins, including streptavidin and
oligohistidine-tagged proteins that bind to these small head groups on cell surfaces.[57, 60–
62, 70] To illustrate the subcellular distribution and receptor-like activity of green
fluorescent 1 in a suspension cell line, confocal laser scanning micrographs of human Jurkat
cells treated with this compound followed by addition of a red fluorescent antifluorescein
antibody at two time points are shown in Figure 6. These images show the localization of 1
on cell surfaces and in early endosomes, and time-dependent endocytic cellular uptake of
this IgG dependent on treatment of cells with 1.
The structure of the linker region and head group of cholesterylamine-derived synthetic
receptors affects the ability of these compounds to bind cell surfaces, partition between the
plasma membrane and early/recycling endosomes, and promote the uptake of impermeable
ligands.[61] Correspondingly, treatment of cells with optimized synthetic receptors can
enhance the uptake of proteins and other ligands by over 100-fold as quantified by flow
cytometry.[61, 62] Ligands internalized in this way are delivered to late endosomes and
lysosomes as evidenced by colocalization of fluorescent derivatives with EGFP-lgp120[61]
or DiI-LDL.[72] Additionally, optimized synthetic receptors exhibit recycling half-lives of
approximately 3 min at 37°C in living Jurkat lymphocytes.[61] This value is similar to the
recycling kinetics of free cholesterol,[44] C6-NBD sphingomyelin,[73] and the LDL
receptor[12] in other mammalian cell lines.
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3.2. A synthetic Fc receptor
Cholesterylamines have been shown to engage major endocytic membrane trafficking
pathways occupied by many natural cell surface receptors. To probe the ability of these
compounds to mimic natural Fc receptors (FcR) such as GPI-linked human FcγRIIIB
(CD16),[9] our laboratory previously synthesized a derivative of the FcIII cyclic peptide,
[74] a compound with high affinity and specificity (Ki = 25 nM) for the Fc region of human
IgG, linked to a close analogue of cholesterylamine, 3β-amino-5α-cholestane
(dihydrocholesterylamine).[72] The structure of a minimalistic synthetic Fc receptor (sFcR)
and a model of this sFcR bound to the Fc region of human IgG are shown in Figure 7
(panels A–B). Human Jurkat lymphocytes do not express FcRs, and treatment of this cell
line with fluorescent human IgG alone does not result in appreciable uptake of the antibody
(Figure 7, panel C). However, Jurkat cells treated with the sFcR and fluorescent human IgG
showed dose-dependent uptake of this fluorescent antibody (Figure 7, panel D). When these
cells were compared with human THP-1 cells that express the natural FcRs FcγRI and
FcγRII, Jurkat cells treated with one micromolar sFcR revealed greater uptake of human
IgG (Figure 7, panel E).[72]
The sFcR rapidly inserted into and readily effluxed from cellular plasma membranes.
Comparison with fluorescent bead standards and analysis by flow cytometry revealed that
treatment of Jurkat cells with one micromolar sFcR for 1 hour installed about 6.2 × 105
molecules of sFcR per cell surface. Another major population of this compound resided in
early/recycling endosomes, and rapid cycling between these subcellular locations was
observed.[72] Under these conditions, the abundance of sFcR on Jurkat cell surfaces was
substantially higher than the natural Fc receptors FcγRI (~1.1 × 104 / cell) and FcγRII (~3 ×
104 / cell) found on THP-1 monocyte cells. However, treatment of Jurkat cells with sFcR
followed by a single wash with media resulted in rapid shedding of this compound from cell
surfaces with a half-life of 0.6 hours. Based on recent studies of cholesterylamines as
substrates for reverse cholesterol transport,[71] shedding of the sFcR from cells likely
involves this natural mechanism of cholesterol efflux.
In some autoimmune diseases, circulating autoreactive antibodies cause tissue damage and
inflammation. As a consequence, it has been proposed that sFcRs may have therapeutic
utility by promoting the cellular uptake and lysosomal degradation of human IgG in vivo.
[72] In this novel therapeutic approach, injection of sFcRs might enable these compounds to
insert into plasma membranes of diverse mammalian cells and remove circulating IgG from
the extracellular environment to reduce the concentration of these ligands. To support this
idea, studies of a simple cell culture model showed that addition of the sFcR (Figure 7) to
media containing Jurkat lymphocyte cells depletes extracellular IgG as a consequence of
synthetic receptor-mediated endocytosis.[72] This approach is conceptually similar to the
effective but costly clinical treatment of autoimmune disease with intravenous
immunoglobulin-G (IVIG), which promotes the catabolism of antibodies in vivo including
pathogenic IgG.[75] Potential therapeutic applications of sFcRs are worthy of further
exploration because IVIG is beneficial for treating a number of autoimmune disorders
including multiple sclerosis, myasthenia gravis, pemphigus, Wegener’s granulomatosis,
Churg-Strauss syndrome, and chronic inflammatory demyelinating polyneuropathy, among
other diseases. Although the development of synthetic cell surface receptors as agents for
depleting endogenous ligands is an intriguing new concept, additional preclinical studies are
necessary to validate this approach in vivo.
3.3. A synthetic vancomycin receptor
To promote receptor-mediated delivery, a wide variety of drugs and probes have been linked
to ligands of natural cell surface receptors. These ligands include LDL, transferrin, folate,
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vitamin B12, and many others.[76] By coupling drugs to these ligands, cells expressing
cognate receptors accumulate these drug-ligand complexes in late endosomes and
lysosomes. Hydrolysis of functional groups or cleavage of disulfides linking drugs to ligands
can release therapeutic agents. This approach has also been used to target receptors involved
in receptor-mediated transcytosis to access natural pathways for delivery of nutrients across
membranes such as the blood-brain barrier.[77]
To explore the potential utility of synthetic receptor-mediated drug delivery, termed
synthetic receptor targeting, our laboratory designed[78] a cholesterylamine linked to the
peptide sequence D-Phe-D-Ala. This dipeptide binds[79] the glycopeptide antibiotic
vancomycin, a drug of last resort against gram positive pathogens such as methicillin-
resistant Staphylococcus aureus.[80] As shown in Figure 8 (panel A), this synthetic
vancomycin receptor (sVancoR) was proposed to bind cellular plasma membranes, project
the vancomycin-binding motif from cell surfaces, and promote endocytic delivery of
vancomycin into mammalian cells. Treatment of normal mammalian cells with sVancoR
and the vancomycin ligand was proposed to deliver this ligand into lysosomes, where the
antibiotic would be degraded. In contrast, this delivery of vancomycin into mammalian cells
infected with the gram-positive intracellular pathogen Listeria monocytogenes was
hypothesized to release vancomycin from endosomes. Expression of the membrane-lytic
protein listeriolysin O (LLO)[81, 82] by L. monocytogenes was proposed to trigger release
of the antibiotic because LLO enables this pathogen to escape from phagosomes and enter
the cytoplasm.[83] Consistent with this hypothesis, sVancoR was shown by confocal laser
scanning microscopy of normal J-774 mouse macrophage cells to promote endocytosis of a
fluorescent conjugate of vancomycin, resulting in its encapsulation in late endosomes/
lysosomes (Figure 8, panel B). However, under the same conditions, in cells infected with L.
monocytogenes, fluorescent vancomycin was observed to escape from endosomes and
diffuse throughout the cytosol and nucleus (Figure 8, panel C).
In human HeLa cells infected with L. monocytogenes, treatment with vancomycin and
sVancoR eradicated this intracellular pathogen (Figure 8, panel D). Moreover, sVancoR and
vancomycin rescued HeLa cells from the lethal effects of this pathogen (Figure 8, panel E).
Control compounds that do not bind vancomycin or that exhibit lower affinity for cellular
plasma membranes did not show these beneficial effects, further supporting the hypothesis
that sVancoR does not simply permeabilize cells, but rather binds vancomycin on cell
surfaces and promotes endocytosis by mimicking the trafficking of natural cell surface
receptors.[78]
Studies of sVancoR in vivo in mice examined the ability of this compound to affect the
tissue distribution of a fluorescent vancomycin conjugate.[78] In these experiments, mice
were injected intraperitoneally with the fluorescent vancomycin alone or the fluorescent
vancomycin and the sVancoR at 50 mg/kg. After eight hours, the tissues shown in Figure 8
(panel F) were harvested, single cell populations were prepared, and cellular fluorescence
was analyzed by flow cytometry. These studies revealed that sVancoR substantially
enhances the accumulation of fluorescent vancomycin in a wide range of tissues, particularly
in skeletal muscle, pancreas, spleen, liver and brain. The synthetic receptor-mediated
accumulation of fluorescent vancomycin in the brain is of particular interest given that less
than 2% of all drugs are capable of penetrating the blood-brain barrier. The brain studies of
sVancoR analyzed all cells isolated from this organ by flow cytometry, and the distribution
among different cell types within the brain was not determined. Consequently, more detailed
studies are needed to determine the magnitude of delivery into different cell types. If
cholesterylamine-derived synthetic receptors can be demonstrated to efficiently engage
receptor-mediated transcytosis pathways into the CNS in vivo, this approach could provide
important new tools for accessing this poorly accessible tissue.
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3.4. Related synthetic compounds that escape from endosomes
Receptor-mediated endocytosis is a highly efficient cellular uptake mechanism. Ligands
internalized through this process are encapsulated in membrane-sealed endosomes and are
typically shuttled into lysosomes containing highly hydrolytic enzymes. As a consequence,
many therapeutics and probes internalized through this route remain trapped in these
compartments and do not reach the cytosol or nucleus in high concentrations. Although
many viruses enter cells through endocytic mechanisms by mimicking the uptake of natural
ligands, these pathogens have evolved to avoid degradation in lysosomes. For example,
SV40 accesses alternative membrane trafficking pathways to bypass lysosomes, enveloped
viruses such as influenza escape from endosomes by fusion of viral envelopes with
endosomal membranes,[84] and non-enveloped viruses produce peptides or proteins that
disrupt membranes at low pH.[33] Previously reported studies of endosome disruptive
peptides, proteins, and polymers have extensively focused on pH-dependent fragments and
mimics of hydrophobic/acidic fusogenic proteins of enveloped viruses such as influenza.
Protonation of glutamic acids and other acidic residues[85] of these peptides in endosomes
enhances hydrophobicity to promote interaction with and destabilization of membranes.[86]
Alternatively, weakly basic endosomolytic monoamines that become increasingly
protonated in endosomes, as well as pH-labile covalent bonds integrated into delivery
systems, have also been used to disrupt the structure and function of endosomes. These and
related approaches have been recently reviewed.[87–89]
We have investigated the delivery of synthetic membrane-active peptides into early
endosomes using cholesterylamines. The incorporation of glutamic acid residues proximal to
N-alkyl-3β-cholesterylamine can be used to preferentially localize these compounds in early
endosomes compared with the plasma membrane of living cells, providing a unique platform
for targeting molecules to these intracellular compartments.[90] By linking a membrane-
lytic peptide termed PC-4[91] to an N-alkyl-cholesterylamine, we demonstrated that a
disulfide-linked fluorescent probe can be released from early endosomes into the cytoplasm
and nucleus of living mammalian cells.[90] This novel two-component delivery system
employed the endosome disruptor (3) shown in Figure 9 (panel A). This cholesterylamine-
linked endosome disruptor (3) was proposed to trigger cleavage of the disulfide of the
fluorescent cholesterylamine 4 and release fluorophore 5 (Figure 9, panel B) into the cytosol
and nucleus of animal cells through the mechanism shown in Figure 9 (Panel C). This
mechanism is based on the observation that, like the extracellular environment, endosomes
are oxidizing[92] and disruption of these compartments could allow reduced glutathione
(GSH), present at high concentrations in the cytosol, to cleave disulfides targeted to the
lumen of these organelles.
Confocal laser scanning microscopy of living Jurkat lymphocyte cells treated with the
cholesterylamine-linked fluorescent disulfide (4) revealed that this compound accumulates
to high levels in early endosomes (Figure 9, panel D). In contrast, when the
cholesterylamine-linked endosome disruptor (3) is coadministered with 4, the disulfide of 4
is cleaved within 14 hours, and the fluorescence of 5 can be observed throughout the
cytoplasm and nucleus (Figure 9, panel E). This method for disruption of early endosomes
appears to be effective in a wide variety of mammalian cells. In Jurkat lymphocytes, the
efficacy of endosome disruption by 4 was quantified by flow cytometry as EC50=1.6 μM.
This value was obtained by measuring the enhancement of fluorescence associated with
release of the pH-sensitive carboxyfluorescein group of 5 from acidic endosomes into the
neutral cytosol. Toxicity of 3 to Jurkat lymphocytes after treatment for 48 hours required
higher concentrations (IC50=9.0 μM), indicating useful selectivity of release of the probe
over toxic effects to cells. This selectivity likely relates to the pH-dependent membrane-lytic
activity of the PC4 peptide[91] and effective targeting of this peptide to early endosomes by
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the linked cholesterylamine. Although a number of synthetic agents have been shown to
disrupt endosomes of mammalian cells,[87–89] the ability of cholesterylamine to target less
hydrolytic early/recycling endosomes and release cargo from these compartments may be
beneficial for the delivery of sensitive materials such as nucleic acids and proteins into the
cytosol.
4. Other approaches
A number of diverse methods for cell surface engineering have been reported, and a
comprehensive review on this topic was recently published.[93] Methods that mimic natural
cell surface receptors include a technique termed “protein painting”[94–97] in which
proteins linked to glycoinositol phospholipids are added to cells and become incorporated
into cellular plasma membranes. This approach has been used to study cellular signaling,
plasma membrane organization, and recognition of modified cell surfaces by the immune
system. Related recombinant GPI-linked proteins have been used to protect vasculature from
immune responses to transplanted organs.[98] Because GPI-linked proteins undergo
clathrin-independent endocytosis, Jurkat lymphocytes treated with a GPI-linked variant of
the immunoglobulin Fc receptor FcγRIII will endocytose ligands that bind this receptor.[99]
Single-chain antibodies covalently linked to lipids have been used to construct related cell
surface receptors.[96] Similarly, palmitoylated Protein A and Protein G can be incorporated
into cellular plasma membranes and have been used to create artificial cell surface receptors
that bind antibodies or other proteins fused to antibody Fc regions.[100–103] Similarly,
recombinant diphtheria toxin T domain has been used to anchor the IgG-binding protein ZZ
to cellular plasma membranes.[104, 105] Using synthetic glycopolymers, Bertozzi and
coworkers created mimics of cell surface mucins that recognize glycan-binding proteins and
become internalized into early endosomes.[39] This chemical approach was used to study
cell surface phenomena with a level of molecular control that cannot be obtained using
conventional biological approaches. Other polymers have also been used to display binding
groups from cell surfaces,[106] and promote the uptake of impermeable ligands.[107] A
driving force behind some of these strategies has been to enhance the immunogenicity of
treated tumor cells as an approach to create potential cancer vaccines. Coating of cells with
receptor-like proteins has also been used as a strategy to promote cell-cell interactions such
as targeting of stem cells to sites of inflammation or injury.
5. Conclusions and perspectives
The chemical biology approach of mimicry of membrane-associated biomolecules such as
cholesterol can be used to design prosthetic molecules that become seamlessly incorporated
into cellular plasma membranes. Although many membrane-associated biomolecules
including proteins, lipids, and carbohydrates[108, 109] all have the potential to be mimicked
in this way, our laboratory has focused on constructing synthetic cell surface receptors from
derivatives of cholesterylamine, a cholesterol analogue easily prepared from cholesterol.[56]
These mimics of cholesterol are a particularly useful platform for these studies because they
can be readily linked to ligand binding motifs, many of these compounds become selectively
inserted into the exofacial leaflet of plasma membranes of living mammalian cells, and these
compounds can rapidly cycle between the cell surface and early/recycling endosomes.
Because cholesterylamines can be designed to not only deliver ligands into endosomes, but
can also be linked to membrane-lytic peptides that disrupt these compartments and release
linked cargo into the cytoplasm and nucleus,[90] this platform may be useful for the
development of improved methods for intracellular delivery of a wide variety of poorly
permeable agents.
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Therapeutic applications of synthetic cell surface receptors are at an early stage of
development. Treatment of cancer cells with receptor-like molecules has been proposed as a
strategy to enhance immunogenicity for construction of cancer vaccines[96, 104] and to
target stem cells to sites of inflammation and injury.[100, 102] Another intriguing new
concept involves the potential use of synthetic cell surface receptors to deplete endogenous
extracellular ligands.[72] Towards this end, a synthetic Fc receptor (sFcR) that binds human
IgG was used to generate preliminary in vitro proof-of-concept that this compound depletes
IgG from cell culture media by promoting its endocytic uptake and lysosomal degradation.
If this strategy can be validated in vivo, the depletion of circulating pathogenic IgG,
responsible for some autoimmune diseases, might be another useful application of this
approach.
As a new strategy for drug delivery, synthetic receptor-mediated cellular uptake of the cell-
impermeable antibiotic vancomycin has been examined.[78] Cells treated with both a
cholesterylamine linked to the vancomycin-binding motif D-Phe-D-Ala and vancomycin as
a ligand eradicated intracellular L. monocytogenes in infected HeLa cells, rescued these
mammalian host cells from lethal effects of this pathogen, and enhanced the tissue
distribution of a fluorescent derivative of vancomycin in mice in vivo. Although this
approach is promising, vancomycin is known to have intrinsic liabilities associated with
toxicity,[80] and other cell-permeable antibiotics are effective against intracellular
pathogenic bacteria. Consequently, the delivery of vancomycin using this approach may be
of limited clinical utility. However, this proof-of-concept that a synthetic receptor that binds
vancomycin can be used to extend the range of its intracellular antibiotic activity to the
cytoplasm of mammalian cells should encourage studies of other drug delivery systems
based on this approach.
Synthetic receptor-mediated endocytosis of vancomycin by mammalian cells infected with
L. monocytogenes resulted in escape of this antibiotic from endosomes into the cytoplasm
and nucleus. This change in subcellular distribution in the presence of this pathogen is likely
due to expression of the bacterial protein LLO, which enables this pathogen to escape
entrapment in intracellular membrane-sealed phagosomes.[81–83] Based on this
observation, membrane-lytic peptides linked to cholesterylamines have been investigated.
These studies led to the discovery that delivery of the membrane-lytic peptide PC4 into
early/recycling endosomes by a cholesterylamine could effectively release a disulfide-linked
fluorophore into the cytoplasm and nucleus of a variety of mammalian cell lines.[90] Further
development of this strategy could focus on improving the potency and efficacy of these
endosome disruptive agents, establish the range of cargo sizes that can be released by these
compounds, and work to overcome challenges in therapeutic delivery of biomolecules such
as RNAi. The delivery of short interfering RNA (siRNA) with this approach is especially
promising given that cholesterol-conjugated siRNAs can silence genes both in vitro and in
vivo, particularly in the liver.[110–113] Examination of the biological consequences of
endosome disruption may be useful for optimization of these compounds. For example,
silica crystals and aluminum salts have been shown to disrupt lysosomes and release
cathepsin B, activating inflammasomes that function as sensors of lysosomal damage.[114]
The development of potent synthetic compounds that efficiently release cargo by targeting
and selectively disrupting early/recycling endosomes without triggering inflammasomes or
other detrimental biological responses could provide important new tools for the delivery of
therapeutics and probes.
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Natural receptors and ligands involved in receptor-mediated endocytosis. From left to right,
X-ray crystal structures of the extracellular domains of the human low-density lipoprotein
(LDL) receptor, the human transferrin receptor, and FcγRIIIB are shown illustrating the
nature of association with the plasma membrane. A structure of the ligand LDL determined
by electron cryomicroscopy is at the upper left (reduced in scale; image courtesy of Dr. Dr.
Wah Chiu, Baylor College of Medicine). Other ligands shown from left to right include
receptor-bound transferrin, receptor-bound Fc region of human IgG, the SV40 capsid
(reduced in scale; image courtesy of Dr. Ten Feizi, Imperial College, London), and the VP1
pentamer of the SV40 capsid bound to the head group of ganglioside GM1.
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Endocytic trafficking of receptors and ligands. This model illustrates uptake of low-density
lipoprotein (LDL) mediated by the LDL receptor (LDLR), diferric transferrin (TF-Fe3+)
internalized by the transferrin receptor (TFR), entry of cholera toxin (CTX) and simian
virus-40 (SV40) after binding to ganglioside GM1, and trafficking of
glycosylphosphatidylinositol-anchored proteins (GPI-AP). Ligand-bound LDLR and TFR
undergo clathrin-mediated endocytosis, whereas binding of CTX and SV40 to GM1
primarily results in endocytic uptake via clathrin-independent carriers (CLIC) and
trafficking through GPI-enriched endocytic compartments (GEEC). The receptors undergo
plasma membrane recycling, LDL is degraded in lysosomes, and transferrin remains bound
to its receptor, releasing iron in sorting endosomes. CTX and SV40 traffic to the ER and
penetrate into the cytosol, resulting in toxicity or infection respectively. The t1/2 and pH
values are approximate and cell-type dependent.
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Structures of cholesterol, cholesterylamine, and representative fluorescent analogues.
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Confocal laser scanning and differential interference contrast microscopy of living Jurkat
lymphocytes treated with fluorescent probes. These micrographs illustrate the rapid binding
of the green fluorescent cholesterol mimic 1 to cellular plasma membranes (panel A) and the
accumulation of this compound in early/recycling endosomes (panels B and D). A
comparison of the divergent trafficking of green fluorescent transferrin-AlexaFluor-488 and
red fluorescent DiI-LDL is shown in panel C. In panel D, extensive colocalization of green
fluorescent 1 with red fluorescent transferrin-AlexaFluor-647 is observed. In contrast, green
fluorescent 22-NBD cholesterol does not remain associated with cellular plasma membranes
and traffics to the Golgi apparatus and nuclear membrane (panels E-F). The Leica SPE
microscope settings in panels A, B, E, and F are identical (high resolution 3 × scans). The
images shown in panels C and D were acquired as identical rapid single scans for
examination of colocalization of the red and green channels. Scale bar: 10 μm.
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Structures of the GPI-anchor of human erythrocyte acetylcholinesterase as a prototypical
membrane anchor found in GPI-linked receptors, the small natural receptor ganglioside
GM1, and examples of small synthetic cell surface receptors (1, 2).
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Confocal laser scanning and DIC micrographs of Jurkat lymphocytes treated with the green
fluorescent synthetic receptor PG-Glu-β-Ala-cholesterylamine (1) followed by rabbit
antifluorescein IgG conjugated to the red fluorescent Cy5 fluorophore.
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Panel A: Structure of a synthetic Fc receptor (sFcR). Panel B: Model of sFcR embedded in
the plasma membrane and bound to the Fc region of human IgG. Panels C–D: confocal laser
scanning (left) and differential interference contrast (right) micrographs of Jurkat
lymphocytes treated for 4 hours as shown. Scale bar: 10 μm. Panel E: Cellular uptake of
fluorescent human IgG (0.5 μM, 4 hours) by THP-1 cells and Jurkat cells treated with sFcR
as quantified by flow cytometry.
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Panel A: Structure of the synthetic vancomycin receptor (sVancoR) and a model illustrating
synthetic receptor-mediated delivery of the antibiotic vancomycin. Panels B–C: Confocal
laser scanning (left) and differential interference contrast (right) microscopy of living J-774
macrophages alone (Panel B) and infected with L. monocytogenes (Panel C). Prior to
microscopy, sVancoR (10 μM) was added to cells for 1 hour at 37 °C, cells were washed,
and fluorescent vancomycin conjugate (3.6 μM) was added for 2 hours at 37 °C. Scale bar:
10 μm. Panel D: Eradication of intracellular L. monocytogenes in HeLa cells dependent on
the concentration of sVancoR as determined by subculture of bacteria. Panel E: Treatment
with sVancoR enables vancomycin to prevent toxicity of L. monocytogenes to HeLa host
cells. Panel F: Distribution of fluorescent vancomycin in mice 8 hours after intraperitoneal
injection as shown. Fluorescence of cells isolated from tissues was analyzed by flow
cytometry.
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Structures of the cholesterylamine-PC4 endosome disruptor (3, panel A), a fluorescent
disulfide-linked cholesterylamine (4, panel B), and products of cleavage of 4 by reduced
glutathione (GSH, panel B). Panel C: Proposed mechanism of release of fluorescent probe 5
upon disruption of early endosomes. Panels D–E: Confocal fluorescence (left) and DIC
(right) micrographs of living Jurkat lymphocytes treated with 4 (2.5 μM) for 12 hours. In
Panel E, cells were additionally treated with endosome disruptor 3 (2 μM). Scale bars = 10
μm. Panel F: efficacy of release of fluorescent probe 5 as analyzed by flow cytometry. Panel
G: Toxicity to Jurkat cells after incubation with 3 for 48 hours at 37 °C as analyzed by flow
cytometry.
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